Toxicity patterns of cytotoxic drugs

Investigational New Drugs

Volumn 21, Issue 2, 2003, Pages 141-148

  Chatelut, Etienne ^a,b   Delord, Jean Pierre ^a   Canal, Pierre ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Anticancer drugs; Pharmacokinetic relationships; Topotecan pharmacodynamic

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DRUG METABOLITE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; NITROSOUREA DERIVATIVE; OXAZAPHOSPHORINE DERIVATIVE; PACLITAXEL; TOPOTECAN;

AREA UNDER THE CURVE; BIOTRANSFORMATION; BLOOD TOXICITY; BONE MARROW TOXICITY; CABBAGE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; CHRONOPHARMACOLOGY; CORRELATION ANALYSIS; CYTOTOXICITY; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG POTENTIATION; DRUG TOLERANCE; DRUG TRANSFORMATION; GENETIC POLYMORPHISM; GROUPS BY AGE; HUMAN; LEUKEMIA; MAXIMUM PERMISSIBLE DOSE; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TOXICITY; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; TOPOTECAN;

EID: 0037812503     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023565227808     Document Type: Review

References (70)

1. Hryniuk WM: Is more better? J Clin Oncol 4: 621-622, 1986.
2. Alberts DS, Dorr RT: New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumors. Oncologist 3: 15-34, 1998
3. Gonzales-Vitale JC. Hayes DM. Cvitkovic E, Sternberg SS: The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39: 1362-1371, 1977
4. Robert J: Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet 26: 428-438, 1994
5. Schneider DT, Hilgenfeld E, Schwabe D, Behnisch W, Zoubek A, Wessalowski R, Gobel U: Acute myelogenous leukemia after treatment for malignant germ cell tumors in children. J Clin Oncol 17: 3226-3233, 1999
6. Macdonald JS: Toxicity of 5-fluorouracil. Oncology (Huntingt) 13: 33-34, 1999
7. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ: Pharmacodynamics in cancer therapy. J Clin Oncol 8: 1739-1753, 1990
8. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M: Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80: 2729-2734, 1992
9. Baum C, Peinert S, Carpinteiro A, Eckert HG, Fairbairn LJ: Genetic modification of haematopoietic cells for combined resistance to podophyllotoxins, other agents covered by MDR1-mediated efflux activity and nitrosoureas. Bone Marrow Transplant 25(suppl 2): S71-S74, 2000
10. Otsuki T, Sakaguchi H, Yamada O, Yawata Y, Ueki A: Effect of the nitrosourea anti-tumor chemotherapeutical agent MCNU on five human myeloma cell lines. Oncol Rep 5: 827-832, 1998
11. Schein PS, Bull JM, Doukas D, Hoth D: Sensitivity of human and murine hematopoietic precursor cells to 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 38: 257-260, 1978
12. Goldwasser F, Buthaud X, Gross M, Bleuzen P, Cvitkovic E, Voinea A, Jasmin C, Romain D, Misset JL: Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. Anticancer Drugs 10: 263-265, 1999
13. Verwey J, de Vries J, Pinedo HM: Mitomycin C-induced renal toxicity, a dose-dependent side effect? Eur J Cancer Clin Oncol 23: 195-199, 1987
14. Pivot X, Guardiola E, Etienne M, Thyss A, Foa C, Otto J, Schneider M, Magne N, Bensadoun RJ, Renee N, Milano G: An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. Eur J Cancer 36: 852-857, 2000
15. Pujol JL, Douillard JY, Riviere A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T: Dose-intensity of a four-drug chemotherapy regimen with of without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 15: 2082-2089, 1997
16. Tjan-Heijnen VC, Postmus PE, Wagener DJ: Dose intensification of chemotherapy and the role of granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor in small cell lung cancer. Anticancer Drugs 8: 49-564, 1997
17. Newell DR: Pharmacokinetic determinants of the activity and toxicity of antitumour agents. Cancer Surv 8: 557-603, 1989
18. Egorin MJ, Reyno LM, Canetta RM, Jodrell DI, Swenerton KD, Pater JL, Burroughs JN, Novak MJ, Sridhara R: Modeling toxicity and response in carboplatin-based combination chemotherapy. Semin Oncol 21: 7-19, 1994
19. Canal P, Chatelut E, Guichard S: Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 56: 1019-1038, 1998
20. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180-190, 1995
21. Cvitkovic E, Bekradda M: Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 26: 647-662, 1999
22. Pignon T, Lacarelle B, Duffaud F, Guillet P, Catalin J, Durand A, Monjanel S, Favre R: Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 33: 420-424, 1994
23. Delepine N, Delepine G, Cornille H, Brion F, Arnaud P, Desbois JC: Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 15: 489-494, 1995
24. Calvert H, Judson I, Van der Vijgh WJ: Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surv 17: 189-217, 1993
25. Perdaems N, Bachaud JM, Rouzaud P, Murris-Espin M, Hermant C, Mihura J, Lochon I, Houin G, Canal P, Chatelut E: Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. Eur J Clin Pharmacol 54: 677-683, 1998
26. Goa KL, Faulds D: Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging 5: 200-234, 1994
27. Balis FM, Holcenberg JS, Bleyer WA: Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 8: 202-232, 1983
28. Peters GJ, Schornagel JH, Milano G: A. Clinical pharmacokinetics of anti-metabolites. Cancer Surv 17: 123-156, 1993
29. Schellens JH, Planting AS, Ma J, Maliepaard M, de Vos A, de Boer DM, Verweij J: Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer. Anticancer Drugs 12: 667-675, 2001
30. Joel SP, Shah R, Clark PI, Slevin ML: Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 14: 257-267, 1996
31. Stewart CF: Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 34(suppl): S76-S83, 1994
32. Reyno LM, Egorin MJ, Canetta RM, Jodrell DI, Swenerton KD, Pater JL, Burroughs JN, Novak MJ, Sridhara R: Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 11: 1156-1164, 1993
33. Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J, Egorin MJ: Phase 1 trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 17: 676-684, 1999
34. Calvert AH, Ghokul S, Al Azraqi A, Wright J, Lind M, Bailey N, Highley M, Siddiqui N, Lunec J, Sinha D, Boddy A, Roberts T, Fenwick J: Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene. Semin Oncol 26: 90-94, 1999
35. Bertrand R, O'Connor PM, Kerrigan D, Pommier Y: Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A: 743-748, 1992
36. Fischel JL, Etienne MC, Formento P, Milano G: Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 4: 2529-2535, 1998
37. Gauvin A, Bressolle F, Martineau P, Astre C, Pinguet F: In vitro schedule-dependent interaction between irinotecan and vinorelbine in NC1 H460 non-small cell lung cancer cell line. Anticancer Res 22: 905-912, 2002
38. Perez EA, Buckwalter CA: Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines. Cancer Chemother Pharmacol 41: 448-452, 1998
39. McLeod HL: Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol, 45: 539-544, 1998
40. Balis FM: Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet 11: 223-235, 1986
41. Kohne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M: Chemotherapy in elderly patients with colorectal cancer. Ann Oncol 12: 435-442, 2001
42. Tirelli U, Aapro M, Obrist R, Festen J, Scheider M, Fentiman I, Monfardini S: Cancer treatment and old people. Lancet 338: 114, 1991
43. Knoester PD, Underberg WJ, Beijnen JH: Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients (review). Anticancer Res 13: 1795-1808, 1993
44. Capizzi RL, Oster W: Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Eur J Cancer 31A(suppl 1): S8-S13, 1995
45. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491, 1999
46. Diasio RB, Johnson MR: The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 61: 199-203, 2000
47. Levi F, Brienza S, Metzer G, Depres-Brummer P, Bertheault-Cvitkovic F, Zidani R, Adam R, Misset JL: Implications of chronobiology for 5-fluorouracil (5-FU) efficacy. Adv Exp Med Biol 339: 169-183, 1993
48. Levi F, Metzger G, Massari C, Milano G: Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 38: 1-21, 2000
49. Canal P, Sqalli A, de Forni M, Chevreau C, Pujol A, Bugat R, Roche H, Oustrin J, Houin G: Chronopharmacokinetics of doxorubicin in patients with breast cancer. Eur J Clin Pharmacol 40: 287-291, 1991
50. Hrushesky WJ: Circadian timing of cancer chemotherapy. Science 228: 73-75, 1985
51. Kerr DJ, Lewis C, O'Neil B, Lawson N, Blackie RG, Newell DR, Boxall F, Cox J, Rankin EM, Kaye SB: The myelotoxicity of carboplatin is influenced by the time of its administration. Hematol Oncol 8: 59-63, 1990
52. Smaaland R: Circadian rhythm of cell division. Prog Cell Cycle Res 2: 241-266, 1996
53. Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJ: An overview of the clinical pharmacology of topotecan. Semin Oncol 24: S5-S5, 1997
54. Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C: Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56: 1-12, 1999
55. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A: Effect of prolonged topotecan infusion on topoisomerase I levels: a phase I and pharmacodynamic study. Clin Cancer Res 3: 1245-1252, 1997
56. Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van BV, Hudson I, Von Hoff DD, Verweij J: A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 5: 69-75, 1999
57. Gerrits CJ, Burris H, Schellens JH, Planting AS, van den Burg ME, Rodriguez GI, van BV, Loos WJ, Hudson I, Fields S, Verweij J, Von Hoff DD: Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer 34: 1030-1035, 1998
58. Schellens JH, Creemers GJ, Beijnen JH, Rosing H, Boer-Dennert M, McDonald M, Davies B, Verweij J: Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 73: 1268-1271, 1996
59. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92: 1651-1656, 2000
60. Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC: Sequences of topotecan and cisplatin: phase 1, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 14: 3074-3084, 1996
61. O'Dwyer PJ, LaCreta FP, Haas NB, Halbherr T, Frucht H, Goosenberg E, Yao KS: Clinical, pharmacokinetic and biological studies of topotecan. Cancer Chemother Pharmacol 34(suppl): S46-S52, 1994
62. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Hurowitz L, DeLisa A, Donehower RC, Noe DA: Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 20: 706-713, 1992
63. O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, Chen TL, Sartorius S, Grochow LB: Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 14: 3062-3073, 1996
64. Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD: Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol 18: 2459-2467, 2000
65. Montazeri A, Boucaud M, Lokiec F, Pinguet F, Culine S, Deporte-Fety R, Albin N, Laguerre B, Goupil A, Bugat R, Canal P, Chatelut E: Population pharmacokinetics of topotecan: intraindividual variability in total drug. Cancer Chemother Pharmacol 46: 375-381, 2000
66. Zamboni WC, Houghton PJ, Johnson RK, Hulstein JL, Crom WR, Cheshire PJ, Hanna SK, Richmond LB, Luo X, Stewart CF: Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. J Pharmacol Exp Ther 284: 89-94, 1998
67. Rosing H, van Zomeren DM, Doyle E, ten Bokkel WW, Schellens JH, Bult A, Beijnen JH: Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods. J Chromatogr B Biomed Sci Appl 727: 191-203, 1999
68. Rosing H, van Zomeren DM, Doyle E, Bult A, Beijnen JH: O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan. Anticancer Drugs 9: 587-592, 1998
69. Zamboni WC, Gajjar AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, Stewart CF: Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 4: 783-789, 1998
70. Montazeri A, Culine S, Laguerre B, Pinguet F, Lokiec F, Albin N, Goupil A, Deporte-Fety R, Bugat R, Canal P, Chatelut E: Individual adaptive dosing of topotecan in ovarian cancer. Clin Cancer Res 8: 394-399, 2002